Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients

Kidney International

Volumn 52, Issue 6, 1997, Pages 1651-1655

  Arnadottir, Margret ^a   Berg, Anna Lena ^b   Dallongeville, Jean ^b   Fruchart, Jean Charles ^b   Nilsson ehle, Peter ^b  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b NONE

Author keywords

Acrenocorticotrophic hormone; Hemodialysis; Hypertriglyceridemia; Lipoprotein; Triglycerides; Uremia

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRACOSACTIDE ZINC PHOSPHATE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DYSLIPOPROTEINEMIA; FEMALE; HEMODIALYSIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; UREMIA;

EID: 0031449481     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.498     Document Type: Article

References (22)

1. BRUNZELL JD, ALBERS JJ, HAAS LB, GOLDBERG AP, AGADOA L, SHERRARD DJ: Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 26:903-910, 1977
2. PONTICELLI C, BARBI G, CANTALUPPI A, DONATI C, ANNONI G, BRANCACCIO D: Lipid abnormalities in maintenance dialysis patients and renal transplant recipients. Kidney Int 13(Suppl 8):S72-S78, 1978
3. NESTEL PJ, FIDGE NH, TAN MH: Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 307:329-333, 1982
4. ATTMAN PO, ALAUPOVIC P, GUSTAFSSON A: Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 32:368-375, 1987
5. CHAN MK, PERSAUD J, VARGHESE Z, MOORHEAD JF: Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 25:812-818, 1984
6. ARNADOTTIR M, DALLONGEVILLE J, FRUCHART JC, THYSELL H, NILSSON-EHLE P: Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 48:779-784, 1995
7. ARNADOTTIR M, DALLONGEVILLE J, FRUCHART JC, NILSSON-EHLE P: Very low density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro. Metabolism 45:686-690, 1996
8. RAINE AEG, MARGREITER R, BRUNNER FP, EHRICH JHH, GEERLINGS W, LANDAIS P, LOIRAT C, MALLICK NP, SELWOOD NH, TUFVESSON G, VALDERRABANO F: Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 7(Suppl 2):7-35, 1992
9. KRONENBERG F, KÖNIG P, NEYER U, AUINGER M, PRIBASNIG A, LANG U, REITINGER J, PINTER G, UTERMANN G, DIEPLINGER H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120, 1995
10. DAHLÉN GH, GUYTON JR, ATTAR M, FARMER JA, KAUTZ JA, GOTTO AM: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 74:758-765, 1986
11. BERG AL, NILSSON-EHLE P: Direct effects of ACTH on plasma lipoprotein metabolism in man-Studies in vivo and in vitro. Metabolism 43:90-97, 1994
12. BERG AL, NILSSON-EHLE P: ACTH lowers serum lipids in steroid treated hyperlipemic patients with kidney disease. Kidney Int 50:538-542, 1996
13. RAMIREZ G, BRUEGGEMEYER C, GANGULY A: Counter-regulatory hormonal response to insulin-induced hypoglycemia in patients on chronic hemodialysis. Nephron 49:231-6, 1988
14. SIAMOPOULOS K, ELEFTHERIADES E, PAPPAS M, SFEROPOULOS G, TSOLAS O: Ovine corticotropin-releasing hormone stimulation test in patients with chronic renal failure: Pharmacokinetic properties, and plasma adrenocorticotropic hormone and serum cortisol responses. Horm Res 30:17-21, 1988
15. FRIEDEWALD WT, LEVY RI, FREDRICKSON DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
16. PARSY D, CLAVEY V, FIEVET C, KORA I, DURIEZ P, FRUCHART JC: Quantification of apolipoprotein C-III in serum by a noncompetitive immunoenzymometric assay. Clin Chem 31:1632-1635, 1985
17. NILSSON-EHLE P, EKMAN R: Rapid, simple and specific assays for lipoprotein lipase and hepatic lipase. Artery 3:194-209, 1977
18. PASTERNACK A, VÄNTTINEN T, SOLAKIVI T, KUUSI T, KORTE T: Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 27:163-168, 1987
19. WANNER C, HÖRL WH, LULEY CH, WIELAND H: Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemo-dialysis. Kidney Int 39:754-760, 1991
20. ARNADOTTIR M, KURKUS J, NILSSON-EHLE P: Different types of heparin in hemodialysis: Long-term effects on post-heparin lipases. Scand J Clin Lab Invest 54:515-521, 1994
21. WINDLER E, HAVEL RJ: Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 26:556-565, 1985
22. WANG CS, MCCONATHY WJ, KLOER HU, ALAUPOVIC P: Modulation of lipoprotein lipase activity by apolipoproteins: Effect of apolipoprotein CIII. J Clin Invest 75:384-390, 1985